Abstract
WS5.5 A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection M. Goldman1, A. Schuster2, C. Halliburn3, G. Doring4, The Freedom Study Group. 1Forest Laboratories UK Ltd, Medical, Dartford, Kent, United Kingdom; 2University of Dusseldorf, Paediatrics, Dusselfdorf, Germany; 3Hartington Data Managment and Statitistics, Statistics, London, United Kingdom; 4University of Tubingen, Institute of Medical Microbiology and Hygiene, Tubingen, Germany
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
